????????i?????????? ?????????? ??i????????i??, i????????i???? ???? i????????i??????????i?????????? ?????????????? ??????????-1 (IGF-1) ???? ??????????????i?? Ruk/CIN85. ????????????????, ???? ??????????????i?? Ruk/CIN85 ?? ????i?????????? ???????????????????????????? ?????????????? ???????????? ???????????? MCF-7 ???? ????i?????????????? ???? ???????? ????????????? ??i????????i??, ?????????? ??i???????????????????? ???? ??i?? i????????i???? ???? IGF-1. ????i?? ????????, IGF-1 ???????????? ??????????i???? ???????????????? ????????i??????????i?? ????i?????? MCF-7, ???? ???????????????????????????? Ruk/CIN85, ??????i?????????? ?? ???????????????????????? ????i????????????. ???? i??????????i?? ??????????????i?? Ruk/CIN85, ?????? i ?????????????????? ????????i???????????????????? ??????????????????i ????i?????? MCF-7 ???? ??????????????i???????????? ?? ????????????????????i LY294 002 (i????i??i???????? ?????????????????????? ?????????? PI3K/Akt). ?????????? ??????????, ???????????????? ??????i ??????????????, ???? ???????????? ???????????????? ???? ??????????????i?? ???? ??i????????i?????? ????????????i?????? ???????????????? Ruk/CIN85.

The effects of hypoxia, insulin and insulin-like growth factor 1 (IGF-1) on the Ruk/CIN85 expression are studied. It is demonstrated that the Ruk/CIN85 expression in human breast adenocarcinoma MCF-7 cells is not changed under mild hypoxia but induced upon insulin and IGF-1 treatment. Moreover, the upregulation of Ruk/CIN85 increased the MCF-7 sensitivity to IGF-induced proliferation. Neither induction of Ruk/CIN85 expression nor increase in MCF-7 proliferative activity was observed in the cells pretreated with PI3K/Akt pathway inhibitor LY294002. Therefore, our study revealed new factors that influence Ruk/CIN85 expression and biological activity.